NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Acute Myeloid Leukemia. These NCCN Guidelines™ are currently available as Version 2.2011.
The highlights of the updates:
For induction treatment in children and young adults with acute promyelocytic leukemia (APL), it is noted in a footnote that studies suggest lower doses of all-trans retinoic acid (ATRA) may be used. Under consolidation therapy for APL patients able to tolerate anthracyclines, a footnote is added noting that all the regimens listed include high cumulative doses of cardiotoxic agents and cardiac function of the patient should be assessed prior to initiating anthracycline/mitoxantrone-containing consolidation course.
For patients with low or intermediate risk APL, the consolidation regimen containing arsenic trioxide described in the North American Intergroup Protocol C9710 is added as an option with a category 2A designation.
A new page has been added listing the salvage chemotherapy options for patients with relapsed acute myeloid leukemia (AML). All regimens listed as salvage options have a category 2A designation.
Under supportive care for AML patients, rasburicase is added as an option for tumor lysis prophylaxis and for consideration as initial treatment in patients with rapidly increasing blast counts, high uric acid, or evidence of impaired renal function (both with a category 2A designation).For the complete updated versions of the NCCN Guidelines™ and the NCCN Compendium™ please visit NCCN.org.